TD Cowen downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $58, down from $76, after the company entered into a merger agreement to be acquired by Novo Nordisk (NVO) at a price of $54.00 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Hold Rating on Akero Therapeutics Amid NOVO Acquisition and Regulatory Uncertainties
- Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer
- Akero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Akero Therapeutics downgraded to Hold from Buy at Clear Street
- Akero Therapeutics Acquired by Novo Nordisk for $5.2B